Publications & Reports

Designing malaria vaccines to circumvent antigen variability.

Ouattara A, Barry AE, Dutta S, Remarque EJ, Beeson JG, Plowe CV
Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA; Malaria Research and Training Center, University of Sciences, Techniques and Technology, Bamako, Mali. Electronic address: aouat


Prospects for malaria eradication will be greatly enhanced by an effective vaccine, but parasite genetic diversity poses a major impediment to malaria vaccine efficacy. In recent pre-clinical and field trials, vaccines based on polymorphic Plasmodium falciparum antigens have shown efficacy only against homologous strains, raising the specter of allele-specific immunity such as that which plagues vaccines against influenza and HIV. The most advanced malaria vaccine, RTS,S, targets relatively conserved epitopes on the P. falciparum circumsporozoite protein. After more than 40 years of development and testing, RTS,S, has shown significant but modest efficacy against clinical malaria in phase 2 and 3 trials. Ongoing phase 2 studies of an irradiated sporozoite vaccine will ascertain whether the full protection against homologous experimental malaria challenge conferred by high doses of a whole organism vaccine can provide protection against diverse strains in the field. Here we review and evaluate approaches being taken to design broadly cross-protective malaria vaccines.


  • Journal: Vaccine
  • Published: 13/10/2015
  • Volume: 33
  • Issue: 52
  • Pagination: 7506-7512



Health Issue